Companies Aquestive Therapeutics, Inc.
Aquestive Therapeutics (AQST): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Aquestive Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,496,141FY2023
- $4,181,472FY2024
- $3,493,559FY2025
CEO total pay was $3,493,559 in fiscal 2025, down from $4,181,472 in fiscal 2024.
FY2025: salary $659,885 · bonus $0 · stock awards $1,547,342 · option awards $877,200
Executives and directors
A. Ernest Toth, Jr. · CFODaniel Barber · CEOLori Braender · ExecutiveAbigail L. Jenkins · Independent DirectorGregory B. Brown, M.D · Chair of the BoardJohn S. Cochran · Independent DirectorJulie Krop, M.D · Independent DirectorMarco Taglietti, M.D · Independent DirectorTimothy E. Morris · Independent Director
Frequently asked questions
Who was the highest-paid executive at Aquestive Therapeutics, Inc. in fiscal 2025?
As disclosed, Daniel Barber (President and Chief Executive Officer) was the highest-paid executive at Aquestive Therapeutics, Inc. in fiscal 2025, with total compensation of $3,493,559.
How did shareholders vote on Aquestive Therapeutics, Inc.'s executive compensation?
As disclosed, 92.21% of shareholders supported Aquestive Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Aquestive Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Aquestive Therapeutics, Inc. reported total board compensation of $541,401 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Barber | $659,885 | $0 | $1,547,342 | $877,200 | $409,132 | $0 | $0 | $3,493,559 |
| President and Chief Executive Officer | ||||||||
| Lori Braender | 457,962 | 0 | 524,150 | 129,000 | 237,126 | 0 | 0 | 1,348,238 |
| Corporate Secretary, Former Chief Legal Officer and Chief Compliance Officer | ||||||||
| A. Ernest Toth, Jr. | 442,599 | 0 | 524,150 | 129,000 | 227,798 | 0 | 0 | 1,323,547 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Barber | $3,493,559 | $4,181,472 | $2,496,141 | ↓ −687,913 |
| Lori Braender | 1,348,238 | 1,821,025 | 1,193,965 | ↓ −472,787 |
| A. Ernest Toth, Jr. | 1,323,547 | — | 1,115,887 | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our goal is to provide compensation that emphasizes pay-for-performance, rewarding those who achieve or exceed their goals, and seeking to drive long-term value for our stockholders through the use of both short-term and long-term incentive programs.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Daniel Barber | PSU | — | — | — | — | — | $1,547,342 |
| Daniel Barber | OPTION | — | — | — | — | — | 877,200 |
| Lori Braender | PSU | — | — | — | — | — | 524,150 |
| A. Ernest Toth, Jr. | PSU | — | — | — | — | — | 524,150 |
| A. Ernest Toth, Jr. | OPTION | — | — | — | — | — | 129,000 |
| Lori Braender | OPTION | — | — | — | — | — | 129,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Daniel Barber | $0 | $1,547,342 | $877,200 | 63.8% |
| Lori Braender | 0 | 524,150 | 129,000 | 80.2% |
| A. Ernest Toth, Jr. | 0 | 524,150 | 129,000 | 80.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| A. Ernest Toth, Jr. | Option | 2,500 | 5.3 | — |
| Daniel Barber | Option | 25,997 | 6.54 | — |
| Lori Braender | Option | 40,000 | 0.88 | — |
| A. Ernest Toth, Jr. | Option | 40,000 | 0.88 | — |
| A. Ernest Toth, Jr. | Option | 45,000 | 5.68 | — |
| Daniel Barber | Option | 50,000 | 4.83 | — |
| Lori Braender | Option | 50,625 | 5.68 | — |
| Lori Braender | Option | 60,000 | 1.54 | — |
| Lori Braender | Option | 60,000 | 2.65 | — |
| A. Ernest Toth, Jr. | Option | 60,000 | 2.65 | — |
| A. Ernest Toth, Jr. | PSU | 70,000 | — | 170,800 |
| A. Ernest Toth, Jr. | RSU | 70,000 | 2.55 | — |
| Daniel Barber | Option | 70,000 | 8.05 | — |
| Lori Braender | PSU | 75,000 | — | 183,000 |
| Lori Braender | RSU | 75,000 | 5.3 | — |
| Lori Braender | PSU | 82,500 | — | 232,650 |
| A. Ernest Toth, Jr. | PSU | 82,500 | — | 232,650 |
| Lori Braender | Option | 85,000 | 18.67 | — |
| A. Ernest Toth, Jr. | RSU | 90,000 | — | 511,200 |
| Daniel Barber | Option | 96,507 | 15 | — |
| Daniel Barber | Option | 100,000 | 0.88 | — |
| Daniel Barber | Option | 100,000 | 5.3 | — |
| Lori Braender | Option | 100,000 | 8.05 | — |
| Lori Braender | RSU | 101,250 | — | 575,100 |
| Lori Braender | RSU | 110,000 | — | 291,500 |
| A. Ernest Toth, Jr. | RSU | 110,000 | — | 291,500 |
| Daniel Barber | Option | 110,000 | 1.54 | — |
| A. Ernest Toth, Jr. | Option | 120,000 | 4.04 | — |
| Lori Braender | Option | 160,000 | 2.55 | — |
| Daniel Barber | RSU | 181,950 | — | 1,033,476 |
| Daniel Barber | PSU | 223,500 | — | 545,340 |
| Daniel Barber | Option | 225,000 | 2.55 | — |
| Daniel Barber | Option | 272,925 | 5.68 | — |
| Daniel Barber | RSU | 293,100 | — | 826,542 |
| Daniel Barber | PSU | 293,100 | — | 826,542 |
| Daniel Barber | Option | 408,000 | 2.65 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gregory B. Brown, M.DIndependent · Board Chair · Nominating/Governance · Compensation · Audit | $127,500 | $0 | $143,220 | $0 | $3,921 | $274,641 |
| John S. CochranIndependent · Nominating/Governance (Chair) · Compensation (Chair) | 91,250 | 0 | 143,220 | 0 | 6,449 | 240,919 |
| Timothy E. MorrisIndependent · Compensation · Audit (Chair) | 88,750 | 0 | 143,220 | 0 | 5,642 | 237,612 |
| Julie Krop, M.DIndependent · Compensation · Audit · Science & Technology (Chair) | 90,000 | 0 | 143,220 | 0 | 0 | 233,220 |
| Marco Taglietti, M.DIndependent · Audit · Science & Technology | 68,750 | 0 | 143,220 | 0 | 1,442 | 213,412 |
| Abigail L. JenkinsIndependent · Nominating/Governance | 55,000 | 0 | 143,220 | 0 | 2,697 | 200,917 |
| Daniel BarberEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $143,220 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 17,500 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $521,250 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $20,151 |
| Total cost of the board | $541,401 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Aquestive Therapeutics as a peer
Companies that benchmark against AQST
6 companies name AQST as a compensation peer
- ADC Therapeutics SAADCTFY2025
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- AYTU BIOPHARMA, INCAYTUFY2026
- Esperion Therapeutics, Inc.ESPRFY2024
- SIGA TECHNOLOGIES INCSIGAFY2025
- Xeris Biopharma Holdings, Inc.XERSFY2025
Each company listed discloses AQST in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AQST in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aquestive Therapeutics, Inc. | 2025 | Daniel Barber | $659,885 | $1,547,342 | $877,200 | $409,132 | $3,493,559 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 37,798,609 | 3,192,381 | 1,604,754 | 92.21% | Passed |
| 2025 | 2025-06-11 | 32,454,278 | 6,694,084 | 459,188 | 82.9% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 92.21%a |
| 2025 | 2025-06-11 | 82.9%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of this vote.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Lori Braender | Corporate Secretary | 2026-05-05 | D | 76,147 | $4 | $318,294 | Common | Form 4 ↗ |
| Cassie Jung | Chief Operating Officer | 2026-05-05 | D | 72,734 | 4 | 304,028 | Common | Form 4 ↗ |
| A. Ernest Toth, Jr. | Chief Financial Officer | 2026-05-05 | D | 92,652 | 4 | 387,285 | Common | Form 4 ↗ |
| Daniel Barber | President and CEO | 2026-05-05 | D | 335,922 | 4 | 1,404,154 | Common | Form 4 ↗ |
| Peter E. Boyd | Chief People Officer | 2026-05-05 | D | 56,778 | 4 | 237,332 | Common | Form 4 ↗ |
| Lori Braender | Corporate Secretary | 2026-05-07 | D | 135,690 | 4 | 573,969 | Common | Form 4 ↗ |
| Daniel Barber | President and CEO | 2026-05-15 | D | 8,257 | 4 | 35,413 | Common | Form 4 ↗ |
| Melina Cioffi | SVP, Regulatory Affairs | 2026-05-15 | D | 1,667 | 4 | 6,951 | Common | Form 4 ↗ |
| Thomas A. Zalewski | Chief Legal Officer | 2026-05-18 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas A. Zalewski | Chief Legal Officer | 2026-05-18 | A | 100,000 | 0 | 0 | Common | Form 4 ↗ |
| Sherry Korczynski | Chief Commercial Officer | 2026-06-08 | D | 2,714 | 0 | 0 | Common | Form 4 ↗ |
| Marco Taglietti | Director | 2026-06-10 | A | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John S. Cochran | Director | 2026-06-10 | A | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Krop | Director | 2026-06-10 | A | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory B. Brown | Director | 2026-06-10 | A | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Abigail L. Jenkins | Director | 2026-06-10 | D | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy E. Morris | Director | 2026-06-10 | A | 50,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Barber | President and CEO | 2026-06-15 | D | 25,000 | 4 | 104,010 | Common | Form 4 ↗ |
| Julie Krop | Director | 2026-06-23 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Julie Krop | Director | 2026-06-23 | D | 25,000 | 5 | 125,393 | Common | Form 4 ↗ |
| Julie Krop | Director | 2026-06-23 | A | 25,000 | 1 | 17,830 | Common | Form 4 ↗ |
| Daniel Barber | President and CEO | 2026-07-15 | D | 4,631 | 4 | 18,683 | Common | Form 4 ↗ |
| Daniel Barber | President and CEO | 2026-07-16 | D | 20,369 | 4 | 81,509 | Common | Form 4 ↗ |
| Sherry Korczynski | Chief Commercial Officer | 2026-08-14 | D | 2,714 | 4 | 11,535 | Common | Form 4 ↗ |
| Daniel Barber | Director | 2026-08-17 | D | 25,000 | 4 | 107,168 | Common | Form 4 ↗ |
| Cassie Jung | Chief Operating Officer | 2026-09-03 | D | 4,587 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cassie Jung | Chief Operating Officer | 2026-09-03 | A | 4,587 | 1 | 4,404 | Common | Form 4 ↗ |
| Daniel Barber | Director | 2026-09-08 | D | 91,743 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Barber | Director | 2026-09-08 | A | 91,743 | 1 | 88,073 | Common | Form 4 ↗ |
| Sherry Korczynski | Chief Commercial Officer | 2026-09-09 | D | 8,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sherry Korczynski | Chief Commercial Officer | 2026-09-09 | D | 8,750 | 5 | 45,675 | Common | Form 4 ↗ |
| Sherry Korczynski | Chief Commercial Officer | 2026-09-09 | A | 8,750 | 3 | 23,188 | Common | Form 4 ↗ |
| Peter E. Boyd | Chief People Officer | 2026-09-09 | D | 2,293 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter E. Boyd | Chief People Officer | 2026-09-09 | A | 2,293 | 1 | 2,201 | Common | Form 4 ↗ |
| Daniel Barber | Director | 2026-09-15 | D | 25,000 | 5 | 120,488 | Common | Form 4 ↗ |
| Daniel Barber | Director | 2026-10-15 | D | 25,000 | 4 | 105,600 | Common | Form 4 ↗ |
| John S. Cochran | Director | 2026-10-21 | A | 62,229 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (60 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel Barber. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 25. As printed: 3,493,559. View filing ↗
- Section 01, Lori Braender. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 25. As printed: 1,348,238. View filing ↗
- Section 01, A. Ernest Toth, Jr.. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 25. As printed: 1,323,547. View filing ↗
- Section 03, Daniel Barber PSU. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Barber OPTION. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Lori Braender PSU. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, A. Ernest Toth, Jr. PSU. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, A. Ernest Toth, Jr. OPTION. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Lori Braender OPTION. DEF 14A, filed 2026-04-24. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-04. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Gregory B. Brown, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 274,641. View filing ↗
- Section 08, John S. Cochran. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 240,919. View filing ↗
- Section 08, Timothy E. Morris. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 237,612. View filing ↗
- Section 08, Julie Krop, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 233,220. View filing ↗
- Section 08, Marco Taglietti, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 213,412. View filing ↗
- Section 08, Abigail L. Jenkins. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 200,917. View filing ↗
- Section 08, Daniel Barber. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Lori Braender 2026-05-05. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cassie Jung 2026-05-05. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, A. Ernest Toth, Jr. 2026-05-05. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-05-05. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter E. Boyd 2026-05-05. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lori Braender 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Melina Cioffi 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas A. Zalewski 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas A. Zalewski 2026-05-18. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sherry Korczynski 2026-06-08. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marco Taglietti 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John S. Cochran 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Krop 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory B. Brown 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Abigail L. Jenkins 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy E. Morris 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Krop 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Krop 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Krop 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sherry Korczynski 2026-08-14. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cassie Jung 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cassie Jung 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-09-08. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sherry Korczynski 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sherry Korczynski 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sherry Korczynski 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter E. Boyd 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter E. Boyd 2026-09-09. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Barber 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John S. Cochran 2026-10-21. Form 4, filed 2026-10-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 92.21% (votes for as printed: 37,798,609). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 82.9% (votes for as printed: 32,454,278). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 521,250 + equity 0 + all other 20,151 = 541,401, summed across the director compensation table rows.
- Aquestive Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Aquestive Therapeutics, Inc.'s own proxy. As printed: 3,493,559. View filing ↗